(RTTNews) - Biogen Inc. (BIIB) said new data showed that after nearly two and a half years of treatment (128 weeks) with ADUHELM injection 100 mg/mL for intravenous use, patients in the long-term extension phase of the phase 3 trials continued to experience significant reductions in two key Alzheimer's disease pathologies, amyloid beta plaques and plasma p-tau181.
The company said the data from the long-term extension study showed that ADUHELM significantly reduced amyloid beta plaque levels out to Week 132. The data also showed that ADUHELM continued to decrease plasma p-tau181 levels at 128 weeks.
"These data demonstrate that long-term treatment with ADUHELM continues to reduce the underlying pathologies of Alzheimer's disease beyond two years," said Samantha Budd Haeberlein, SVP, Head of Neurodegeneration Development at Biogen.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
%20(GNK)%20Stock%20Price%2C%20Quote%2C%20News%20%26%20History%20%7C%20Nasdaq&_biz_n=0&rnd=591310&cdn_o=a&_biz_z=1741390898803)
